| Gene symbol | PLK1 | Synonyms | PLK, STPK13 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p12.2 | dbXrefs | |
| Description | polo like kinase 1 | ||||
| GTO ID | GTC1370 |
| Trial ID | NCT01262235 |
| Disease | Adrenocortical Carcinoma | Neuroendocrine Tumor | Cancer |
| Altered gene | PLK1 |
| Therapeutic/Target gene | Target gene |
| Therapy | siRNA |
| Treatment | TKM-080301|PLK1 SNALP|TKM-PLK1 |
| Phase | Phase1|Phase2 |
| Recruitment status | Completed |
| Title | A Phase 1/2 Dose Escalation Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of Intravenous TKM-080301 in Patients With Advanced Solid Tumors |
| Year | 2010 |
| Country | United States |
| Company sponsor | Arbutus Biopharma Corporation |
| Other ID(s) | TKM-PLK1-001 |
| Vector information | |||
|
|||
| Cohort 1 | |||||||||
|
|||||||||